In the midst of an ongoing campaign to boost its profile in the increasingly crowded animal health space, Parnell Pharmaceutical Holdings named two new top executives and one board member to its growing team on Tuesday evening. The Kansas company appointed veterinarian Edward Robb as chief scientific officer and Andy Ferrigno as vice president of global sales. Thomas E. Duley of life science consultancy King & Spalding was named to the company's board of directors.
Julie Gerberding, president of Merck's vaccines unit, will be moving on come mid-December for a new role as executive vice president for strategic communications, global public policy and population health, the company announced Wednesday.
BioClinica has named John Hubbard as its new CEO. Hubbard joins the company from Pfizer, where he worked as senior vice president and worldwide head of development operations.
J. Craig Venter has made new hires at two of his companies.
There's change at the top of a couple of vaccinemakers, with a pair of companies this week announcing upcoming roster moves. For Takeda, that means signing on a new head of vaccine development, while Novartis' vaccine division head will hit the road.
GE has appointed John Flannery as the president and CEO of GE Healthcare. He was previously the SVP of business development at the company. The move comes after the healthcare division shrank a bit during the first half.
Paul Herendeen has been appointed as the new executive vice president and chief financial officer to Zoetis, the animal health industry leader. Reporting to CEO Juan Ramón Alaix, he will oversee the company's finance and IT segments.
Exosome Diagnostics will advance its prostate cancer urine test to market with a new CEO and a change in locale to one of the biggest biotech clusters in the world.
The chief of Philips Healthcare, Deborah DiSanzo, has left the company ahead of what is expected to be disappointing Q2 earnings. The unit will now report directly to CEO Frans van Houten, The Wall Street Journal reported.
At least one third party agrees with Carl Icahn about Forest Laboratories. Institutional Shareholder Services, a proxy advisory firm, has backed two of Icahn's four nominees to the Forest board.